Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccine-derived poliovirus type 1, 2, 3 strains in Japan. 2008

Masae Iwai, and Takenori Takizawa, and Takashi Nakayama, and Kumiko Matsuura, and Hiromu Yoshida, and Sumiyo Hasegawa, and Mayumi Obara, and Eiji Horimoto, and Takeshi Kurata, and Hitoshi Horie
Department of Virology, Toyama Institute of Health, Nakataikoyama, Imizu-shi, Toyama, Japan.

We evaluated the efficacy of Japan's vaccination policy, a 2-dose administration of live oral poliovirus vaccine (OPV) against wild and virulent vaccine-derived poliovirus (VDPV) type 1, 2, 3 strains, by investigating the neutralizing antibody titers of residents in Toyama Prefecture, Japan. Seropositivities against the virulent type 1 and 2 strains were more than 90%, but the values against the virulent type 3 strains were approximately 60%. Also, while geometric mean antibody titers against virulent type 1 and 2 strains were more than 180, those against the virulent type 3 strains were 58-59, and 9-12, in particular, at 10 to 19 y of age. A booster dose of the vaccine for the type 3 virus is recommended for adolescents. However, high herd immunity against type 1, 2 and 3 viruses has been maintained for these 22 y, although the seropositivity against type 3 virus was always lower than other types. Our results suggest that Japan's vaccination policy might be enough to prevent an epidemic of poliomyelitis caused by wild and virulent VDPV type 1, 2, 3 strains, even though the titers against type 3 viruses were the lowest.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011051 Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5) Infantile Paralysis,Polio,Poliomyelitis, Nonpoliovirus,Poliomyelitis, Preparalytic,Encephalitis, Polio,Epidemic Acute Poliomyelitis,Polio Encephalitis,Poliomyelitis Infection,Poliomyelitis, Acute,Acute Poliomyelitis,Acute Poliomyelitis, Epidemic,Infection, Poliomyelitis,Infections, Poliomyelitis,Nonpoliovirus Poliomyelitis,Paralysis, Infantile,Poliomyelitides, Preparalytic,Poliomyelitis Infections,Poliomyelitis, Epidemic Acute,Polios,Preparalytic Poliomyelitis
D011055 Poliovirus Vaccine, Oral A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed) Sabin Vaccine,Oral Poliovirus Vaccine,Vaccine, Oral Poliovirus,Vaccine, Sabin
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Masae Iwai, and Takenori Takizawa, and Takashi Nakayama, and Kumiko Matsuura, and Hiromu Yoshida, and Sumiyo Hasegawa, and Mayumi Obara, and Eiji Horimoto, and Takeshi Kurata, and Hitoshi Horie
January 2006, Acta virologica,
Masae Iwai, and Takenori Takizawa, and Takashi Nakayama, and Kumiko Matsuura, and Hiromu Yoshida, and Sumiyo Hasegawa, and Mayumi Obara, and Eiji Horimoto, and Takeshi Kurata, and Hitoshi Horie
December 1970, JAMA,
Masae Iwai, and Takenori Takizawa, and Takashi Nakayama, and Kumiko Matsuura, and Hiromu Yoshida, and Sumiyo Hasegawa, and Mayumi Obara, and Eiji Horimoto, and Takeshi Kurata, and Hitoshi Horie
January 1978, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale,
Masae Iwai, and Takenori Takizawa, and Takashi Nakayama, and Kumiko Matsuura, and Hiromu Yoshida, and Sumiyo Hasegawa, and Mayumi Obara, and Eiji Horimoto, and Takeshi Kurata, and Hitoshi Horie
October 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Masae Iwai, and Takenori Takizawa, and Takashi Nakayama, and Kumiko Matsuura, and Hiromu Yoshida, and Sumiyo Hasegawa, and Mayumi Obara, and Eiji Horimoto, and Takeshi Kurata, and Hitoshi Horie
April 1967, Japanese journal of medical science & biology,
Masae Iwai, and Takenori Takizawa, and Takashi Nakayama, and Kumiko Matsuura, and Hiromu Yoshida, and Sumiyo Hasegawa, and Mayumi Obara, and Eiji Horimoto, and Takeshi Kurata, and Hitoshi Horie
August 1988, Journal of virology,
Masae Iwai, and Takenori Takizawa, and Takashi Nakayama, and Kumiko Matsuura, and Hiromu Yoshida, and Sumiyo Hasegawa, and Mayumi Obara, and Eiji Horimoto, and Takeshi Kurata, and Hitoshi Horie
June 2002, Journal of virology,
Masae Iwai, and Takenori Takizawa, and Takashi Nakayama, and Kumiko Matsuura, and Hiromu Yoshida, and Sumiyo Hasegawa, and Mayumi Obara, and Eiji Horimoto, and Takeshi Kurata, and Hitoshi Horie
May 1997, The Journal of infectious diseases,
Masae Iwai, and Takenori Takizawa, and Takashi Nakayama, and Kumiko Matsuura, and Hiromu Yoshida, and Sumiyo Hasegawa, and Mayumi Obara, and Eiji Horimoto, and Takeshi Kurata, and Hitoshi Horie
February 1981, Journal of clinical microbiology,
Masae Iwai, and Takenori Takizawa, and Takashi Nakayama, and Kumiko Matsuura, and Hiromu Yoshida, and Sumiyo Hasegawa, and Mayumi Obara, and Eiji Horimoto, and Takeshi Kurata, and Hitoshi Horie
January 2022, Western Pacific surveillance and response journal : WPSAR,
Copied contents to your clipboard!